Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hogenboom Laura, Schoof Lisa G, Gelissen Liza M Y, Mostert Jop, van Rooij Luuk, Hoitsma Elske, van Munster Caspar E P, van Eijk Jeroen, Kalkers Nienke F, Adriani Kirsten S, Vennegoor Anke, Arts Ilse M P, Mensing Liselore, Eurelings Marijke, de Gans Koen, Gerlach Oliver, Hoogervorst Erwin L J, Kloosterziel Mark E, Kragt Jolijn J, Portier Ruben P, Smets Ide, van Geel Björn M, Nielsen Jessica, Roosendaal Christiaan M, Piet Jurgen R, Zeinstra Esther, Groeneveld Onno N, van Oosten Bob W, de Jong Brigit A, Uitdehaag Bernard M J, Strijbis Eva M M, Lissenberg-Witte Birgit I, Killestein Joep, van Kempen Zoé L E
Аннотация
METHODS: This was a prospective cohort study, as part of the ongoing BLOOMS trial, investigating participants randomised for B-cell guided interval dosing of ocrelizumab with ≥ 2 dosing intervals. Coefficients of variation were calculated for time from last ocrelizumab dose to first CD19+ B-cell measurement ≥ 0.01 × 109 cells/L.
RESULTS: Seventy-five participants with a total of 209 B-cell guided intervals were included. Time from last dose to first appearance of CD19+ B-cell count ≥ 0.01 × 109 cells/L showed wide variability between individuals (20.6-72.1 weeks), but the median variation was 5.6% (IQR: 3.1-8.4) within an individual. This translated to a variation of 2 weeks per dosing interval on average.
DISCUSSION: Time to CD19+ B-cell repopulation after each ocrelizumab dose is individually stable. This finding could pave the way for easier and more accessible future personalised interval dosing of B-cell depleting therapies if this stability is confirmed in long-term treatment.